These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 24321464)

  • 1. The role of immunohistochemistry in the diagnosis of flat urothelial lesions: a study using CK20, CK5/6, P53, Cd138, and Her2/Neu.
    Jung S; Wu C; Eslami Z; Tanguay S; Aprikian A; Kassouf W; Brimo F
    Ann Diagn Pathol; 2014 Feb; 18(1):27-32. PubMed ID: 24321464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia.
    Aron M; Luthringer DJ; McKenney JK; Hansel DE; Westfall DE; Parakh R; Mohanty SK; Balzer B; Amin MB
    Am J Surg Pathol; 2013 Dec; 37(12):1815-23. PubMed ID: 24225842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases.
    Oliva E; Pinheiro NF; Heney NM; Kaufman DS; Shipley WU; Gurski C; Spicer B; Paner GP; Gown AM; Amin MB
    Hum Pathol; 2013 May; 44(5):860-6. PubMed ID: 23199526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia.
    Mallofré C; Castillo M; Morente V; Solé M
    Mod Pathol; 2003 Mar; 16(3):187-91. PubMed ID: 12640096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of cytokeratin 5/6, cytokeratin 20, and p16 in the diagnosis of reactive urothelial atypia and noninvasive component of urothelial neoplasia.
    Edgecombe A; Nguyen BN; Djordjevic B; Belanger EC; Mai KT
    Appl Immunohistochem Mol Morphol; 2012 May; 20(3):264-71. PubMed ID: 22498670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens.
    McKenney JK; Desai S; Cohen C; Amin MB
    Am J Surg Pathol; 2001 Aug; 25(8):1074-8. PubMed ID: 11474293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical staining patterns of Ki-67 and p53 in florid reactive urothelial atypia and urothelial carcinoma in situ demonstrate significant overlap.
    Nguyen JK; Przybycin CG; McKenney JK; Magi-Galluzzi C
    Hum Pathol; 2020 Apr; 98():81-88. PubMed ID: 32142835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Could double stain for p53/CK20 be a useful diagnostic tool for the appropriate classification of flat urothelial lesions?
    Di Sciascio L; Ambrosi F; Franceschini T; Giunchi F; Franchini E; Massari F; Bianchi FM; Colecchia M; Fiorentino M; Ricci C
    Pathol Res Pract; 2022 Jun; 234():153937. PubMed ID: 35561522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions.
    Schwarz S; Rechenmacher M; Filbeck T; Knuechel R; Blaszyk H; Hartmann A; Brockhoff G
    J Clin Pathol; 2008 Mar; 61(3):272-7. PubMed ID: 17693577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokeratin 20 and Ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium.
    Yin H; He Q; Li T; Leong AS
    Appl Immunohistochem Mol Morphol; 2006 Sep; 14(3):260-5. PubMed ID: 16932015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference.
    Amin MB; Trpkov K; Lopez-Beltran A; Grignon D;
    Am J Surg Pathol; 2014 Aug; 38(8):e20-34. PubMed ID: 25029121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CK20 versus AMACR and p53 immunostains in evaluation of Urothelial Carcinoma in Situ and Reactive Atypia.
    Neal DJ; Amin MB; Smith SC
    Diagn Pathol; 2020 May; 15(1):61. PubMed ID: 32456709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis of urothelial carcinoma in situ using blue light cystoscopy and the utility of immunohistochemistry in blue light-positive lesions diagnosed as atypical.
    Pederzoli F; Murati Amador B; Samarska I; Lombardo KA; Kates M; Bivalacqua TJ; Matoso A
    Hum Pathol; 2019 Aug; 90():1-7. PubMed ID: 31071342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CK5, CK5/6, and double-stains CK7/CK5 and p53/CK5 discriminate in situ vs invasive urothelial cancer in the prostate.
    Fichtenbaum EJ; Marsh WL; Zynger DL
    Am J Clin Pathol; 2012 Aug; 138(2):190-7. PubMed ID: 22904129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of cytokeratin 20 and Ki-67 as markers of urothelial dysplasia.
    Kunju LP; Lee CT; Montie J; Shah RB
    Pathol Int; 2005 May; 55(5):248-54. PubMed ID: 15871722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysplasia and carcinoma in situ of the urinary bladder.
    Lopez-Beltran A; Marques RC; Montironi R; Reymundo C; Fonseca J; Cheng L
    Anal Quant Cytopathol Histpathol; 2015 Feb; 37(1):29-38. PubMed ID: 26072632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review and meta-analysis of CK20, CD44, Ki67 and p53 as immunohistochemical markers in bladder carcinoma in situ.
    Straccia P; Fiorentino V; Martini M; Pierconti F
    Actas Urol Esp (Engl Ed); 2022 Nov; 46(9):521-530. PubMed ID: 36216762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does the addition of AMACR to CK20 help to diagnose challenging cases of urothelial carcinoma in situ?
    Alston ELJ; Zynger DL
    Diagn Pathol; 2019 Aug; 14(1):91. PubMed ID: 31419984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flat Intraurothelial Neoplasia Exhibiting Diffuse Immunoreactivity for CD44 and Cytokeratin 5 (Urothelial Stem Cell/Basal Cell Markers): A Variant of Intraurothelial Neoplasia Commonly Associated With Muscle-invasive Urothelial Carcinoma.
    Mai KT; Busca A; Belanger EC
    Appl Immunohistochem Mol Morphol; 2017 Aug; 25(7):505-512. PubMed ID: 26990746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Urothelial hyperplastic lesion with endophytic growth pattern: a clinicopathologic study].
    Xiao L; Wang CF; Zhu XZ; Yin YL; Chen Y; Lu C; Yu B
    Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):319-23. PubMed ID: 21756826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.